AMENDMENT

In the Claims:

Please amend claims 1, 22-25, 30, 31, 34 and 35, so that the text of the amended claims read as follows:

B1

1. (Twice Amended) A therapeutic combination product for use in the prevention and/or treatment of asthma comprising (a) a medicament comprising a surface active phospholipid (SAPL) composition in finely divided form, the SAPL composition including a component which enhances spreading of the medicament over a surface at about normal mammalian body temperature and (b) an antiasthma drug, wherein ingredients (a) and (b) are provided in a form for administration together or separately and the product is arranged for delivery of at least one individual inhalable dose, the individual dose or each individual dose comprising said ingredient (a) in an inhalable amount of at least 25mg.

B2

22. (Twice Amended) A combination product as claimed in claim 1, wherein the individual dose or each individual dose comprises said ingredient (a) in an inhalable amount of at least 40mg.

23. (Twice Amended) A combination product as claimed in claim 36, wherein the product is arranged for delivery of ingredient (a) in an inhalable amount of at least 25mg.

24. (Twice Amended) A combination product as claimed in claim 37, wherein the product is arranged for delivery of ingredient (a) in an inhalable amount of at least 25mg.

25. (Twice Amended) A combination product as claimed in claim 1, in which at least ingredient (a) is arranged for sequential delivery of a multiplicity of inhalable doses.

30. (Twice Amended) A delivery device for administering to a patient by inhalation a medicament for the prevention and/or treatment of asthma, the delivery device containing a medicament comprising a surface active phospholipid (SAPL) composition in finely divided form, the SAPL composition including a component which enhances the spreading of the medicament, the delivery device being arranged for delivery of at least one individual dose of the SAPL composition in an inhalable amount of at least 25mg.

31. (Amended) A delivery device for administering to a patient by inhalation a medicament for the prevention or treatment of asthma, the delivery device containing a medicament comprising a first component consisting of one or more phosphatidyl cholines and a second component consisting of one or more compounds selected from the group consisting of phosphatidyl glycerols, phosphatidyl ethanolamines, phosphatidyl serines, phosphatidyl inositols and chlorestyl palmitate, the delivery device being arranged for delivery of at least one individual inhalable dose, the or each individual dose comprising said first component and said second component in a combined inhalable amount of at least 25mg.

34. (Twice Amended) A medicament for use in the control of asthma, comprising (a) a surface active phospholipid (SAPL) composition in finely divided form conjointly with (b) an antiasthma drug, wherein the medicament is arranged for delivery of said SAPL composition in an individual inhalable dosage amount of at least 25mg.

35. (Amended) A combination product for use in the prevention or treatment of asthma comprising

(a) a medicament comprising a first phospholipid component which is capable of binding to lung tissue and a second component which is capable of enhancing the spreading of said first component over an aqueous medium at 37°C, said medicament being in the form of a finely divided powder; and

(b) an antiasthma drug;

the ingredients (a) and (b) being arranged for administration in combination or separately, simultaneously or sequentially, to deliver ingredient (a) in an individual inhalable dosage amount of at least 25mg.

Please add new claims 36 and 37, as follows:

36. (New) A therapeutic combination product for use in the prevention and/or treatment of asthma comprising (a) a medicament comprising a surface active phospholipid (SAPL) composition in finely divided form, the SAPL composition including a component which enhances spreading of the medicament over a surface at about normal mammalian body temperature and (b) an antiasthma drug, wherein ingredients (a) and (b) are provided in a form for separate, simultaneous or sequential, administration and wherein ingredient (a) consists of a first component comprising one or more phosphatidyl cholines and a second component comprising one or more compounds selected from the group consisting of phosphatidyl glycerols, phosphatidyl ethanolamines, phosphatidyl serines, phosphatidyl inositols and chlorestyl palmitate.

37. (New) A therapeutic combination product for use in the prevention and/or treatment of asthma comprising (a) a medicament comprising a surface active phospholipid (SAPL) composition in finely divided form, the SAPL composition including a component which enhances spreading of the medicament over a surface at about normal mammalian body temperature and (b) an antiasthma drug selected from the group consisting of β_2-agonists, cromones, antimuscarinic drugs and leukotriene receptor antagonists, wherein ingredients (a) and (b) are provided in a form for administration together or in a form for administration separately and wherein ingredient (a) consists of a first component comprising one or more phosphatidyl cholines and a second component comprising one or more compounds selected from the group consisting of phosphatidyl glycerols, phosphatidyl ethanolamines, phosphatidyl serines, phosphatidyl inositols and chlorestyl palmitate, said first component and said second component being present in a weight ratio of from 6:4 to 8:2.

RESPONSE

I. Status of the Claims

Prior to the present Action, claims 1-35 were pending and have been examined without entry of a restriction or species election requirement. Presently, claims 1, 22-25, 30, 31, 34 and 35 have been amended without prejudice, to even further improve the clarity of the invention. No claims have been canceled. Claims 36 and 37 have been added, which are unified with the examined claims and fully supported by the present and parent applications.

Claims 1-37 are therefore in the case. According to 37 C.F.R. § 1.121, and for the convenience of the Examiner, a clean copy of the pending claims is included (**Exhibit A**), along with a copy of the pending claims showing the present revisions (**Exhibit B**). The claims in each are marked "(Amended)" and "(New)" where appropriate.